{"id":"antiretroviral-anti-hiv","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Nausea and gastrointestinal disturbance"},{"rate":"5-20","effect":"Headache"},{"rate":"10-25","effect":"Diarrhea"},{"rate":"5-15","effect":"Rash"},{"rate":"variable","effect":"Lipodystrophy and metabolic changes"},{"rate":"1-5","effect":"Hepatotoxicity"},{"rate":"5-15","effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Antiretroviral therapy (ART) encompasses multiple drug classes that work at different stages of the HIV lifecycle. Common mechanisms include reverse transcriptase inhibitors (blocking viral RNA conversion to DNA), protease inhibitors (preventing viral protein maturation), integrase inhibitors (blocking viral DNA integration into the host genome), and entry inhibitors (preventing viral attachment or fusion with CD4+ cells). Combination therapy is standard to suppress viral replication and prevent resistance.","oneSentence":"Antiretroviral drugs inhibit HIV replication by targeting viral enzymes or blocking viral entry into CD4+ T cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:31.036Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (treatment and prevention)"}]},"trialDetails":[{"nctId":"NCT06823596","phase":"NA","title":"The T Cell Activator of Cell Killing (\"TACK\") IT ON\" STUDY","status":"RECRUITING","sponsor":"University of Toronto","startDate":"2025-01-14","conditions":"Hiv","enrollment":26},{"nctId":"NCT05866523","phase":"NA","title":"Teamwork Makes the Dream Work","status":"RECRUITING","sponsor":"Loma Linda University","startDate":"2023-10-16","conditions":"HIV Infections, Inpatient Facility Diagnoses","enrollment":250},{"nctId":"NCT05281510","phase":"PHASE2","title":"Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2022-06-09","conditions":"HIV-1-infection","enrollment":20},{"nctId":"NCT00146094","phase":"NA","title":"Bone Mineral Density (BMD) in HIV Infection","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2003-03","conditions":"Osteopenia, Osteoporosis","enrollment":44},{"nctId":"NCT05780073","phase":"PHASE2","title":"Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment","status":"COMPLETED","sponsor":"Fundació Institut Germans Trias i Pujol","startDate":"2023-10-16","conditions":"HIV Infection Primary","enrollment":60},{"nctId":"NCT06814275","phase":"NA","title":"Project neuroARTEMIS","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2025-04-29","conditions":"Stimulant Use, Human Immunodeficiency Virus (HIV), Depression","enrollment":189},{"nctId":"NCT03800407","phase":"","title":"Contributing Factors for Poor HIV Treatment Response in Children With TB/HIV Coinfection","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-28","conditions":"Tuberculosis, Human Immunodeficiency Virus, Coinfection","enrollment":213},{"nctId":"NCT05582694","phase":"PHASE2","title":"A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-10","conditions":"Multi-Drug Resistant Hiv-1 Infection, HIV-1 Infection","enrollment":""},{"nctId":"NCT04648046","phase":"PHASE1, PHASE2","title":"CAR-T Cells for HIV Infection","status":"RECRUITING","sponsor":"Steven Deeks","startDate":"2021-03-01","conditions":"HIV Infections","enrollment":18},{"nctId":"NCT07031063","phase":"PHASE4","title":"Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-04-01","conditions":"HIV Infection, Metabolic Syndrome, Antiretroviral Treatment","enrollment":124},{"nctId":"NCT02344680","phase":"","title":"Liver Fibrosis in Zambian HIV-HBV Co-infected Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2015-10","conditions":"Human Immunodeficiency Virus, HBV, Fibrosis, Liver","enrollment":303},{"nctId":"NCT03729752","phase":"PHASE1","title":"PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2018-11-01","conditions":"HIV-1-infection","enrollment":30},{"nctId":"NCT03041012","phase":"PHASE2","title":"Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2017-01-20","conditions":"Hiv","enrollment":60},{"nctId":"NCT05668026","phase":"PHASE1, PHASE2","title":"Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2024-04-01","conditions":"HIV-1-infection","enrollment":18},{"nctId":"NCT06738082","phase":"","title":"Influenza Vaccine Elicited Immune Response in Immunocompromised Patients","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2024-10-15","conditions":"Influenza Vaccine, Immunocompromised Patients","enrollment":147},{"nctId":"NCT05494866","phase":"PHASE1","title":"A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma","status":"TERMINATED","sponsor":"German Cancer Research Center","startDate":"2022-12-07","conditions":"CYP3A Inhibitor, Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer","enrollment":6},{"nctId":"NCT03205696","phase":"","title":"Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2017-08-01","conditions":"Human Immunodeficiency Virus","enrollment":101},{"nctId":"NCT05256862","phase":"","title":"Improving Cervical Cancer Screening in Women Living With HIV Attending Chronic Disease Clinics in Semi-rural Tanzania","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-07-27","conditions":"Cervical Cancer Screening","enrollment":2974},{"nctId":"NCT04840199","phase":"PHASE2","title":"A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-04-19","conditions":"HIV Infections, Cytomegalovirus, CMV","enrollment":44},{"nctId":"NCT05784584","phase":"","title":"Early Anti-Retroviral Treatment in HIV- Infected Children","status":"COMPLETED","sponsor":"PENTA Foundation","startDate":"2018-05-01","conditions":"HIV Infections","enrollment":220},{"nctId":"NCT04418037","phase":"PHASE4","title":"DHFS for Medication Adherence Support During Hospital Admissions for Person Living With HIV","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2019-05-15","conditions":"HIV/AIDS","enrollment":16},{"nctId":"NCT03800381","phase":"","title":"Adequacy of the New Pediatric Isoniazid/Rifampin/Pyrazinamide (HRZ) Tablet","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-28","conditions":"Tuberculosis, Human Immunodeficiency Virus, Coinfection","enrollment":92},{"nctId":"NCT05330143","phase":"PHASE2","title":"Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2022-06-28","conditions":"HIV-1-infection, HIV Infections, PD-L1 Gene Mutation","enrollment":19},{"nctId":"NCT02397096","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-09","conditions":"HIV-1 Infection","enrollment":673},{"nctId":"NCT06676410","phase":"PHASE2","title":"Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants","status":"RECRUITING","sponsor":"Code Pharma","startDate":"2023-07-20","conditions":"HIV, HIV Infection","enrollment":40},{"nctId":"NCT04076423","phase":"PHASE4","title":"A Phase IV Study to Assess the Impact of the Change of Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With HIV Infection","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2019-10-10","conditions":"HIV Infections","enrollment":141},{"nctId":"NCT05546242","phase":"PHASE3","title":"Improving HIV-1 Control in Africa with Long Acting Antiretrovirals","status":"ACTIVE_NOT_RECRUITING","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2022-12-08","conditions":"HIV-1-infection","enrollment":540},{"nctId":"NCT05663892","phase":"PHASE4","title":"Drug-Drug Interaction Study in Trans Women Living With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Maple Leaf Research","startDate":"2022-11-23","conditions":"Hiv, Transgenderism","enrollment":45},{"nctId":"NCT02595866","phase":"PHASE1","title":"Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2016-04-04","conditions":"AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":58},{"nctId":"NCT03674983","phase":"NA","title":"PrEP Seguro: Antiretroviral-based HIV Prevention Among Men at High Risk in Mexico","status":"COMPLETED","sponsor":"Brown University","startDate":"2019-05-15","conditions":"HIV Infections","enrollment":310},{"nctId":"NCT03800394","phase":"","title":"Pharmacokinetics of Intracellular TFV-DP and FTC-TP in HIV-infected Adolescents","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-28","conditions":"Human Immunodeficiency Virus (HIV), Tuberculosis, Coinfection","enrollment":52},{"nctId":"NCT04480554","phase":"PHASE2","title":"Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-01-30","conditions":"Opioid-use Disorder, HIV-1-infection, Immune Activation","enrollment":225},{"nctId":"NCT02881762","phase":"PHASE4","title":"Maraviroc Efficacy for Hepatitis C","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2017-06-01","conditions":"Hepatitis C, Human Immunodeficiency Virus","enrollment":10},{"nctId":"NCT04388904","phase":"PHASE4","title":"Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)","status":"COMPLETED","sponsor":"The Crofoot Research Center, Inc.","startDate":"2021-09-01","conditions":"HIV-1-infection","enrollment":75},{"nctId":"NCT04253119","phase":"","title":"ART First-line Treatment Durability in Russia","status":"COMPLETED","sponsor":"MSD Pharmaceuticals LLC","startDate":"2019-11-26","conditions":"HIV-1-infection","enrollment":536},{"nctId":"NCT03809364","phase":"NA","title":"Pilot Test of a Couple-Based Medication Adherence Intervention for HIV-Positive Women and Their Male Partners in South Africa","status":"COMPLETED","sponsor":"University of Maryland, College Park","startDate":"2021-11-01","conditions":"Human Immunodeficiency Virus","enrollment":40},{"nctId":"NCT06107140","phase":"","title":"Duration of Dual Antiretroviral Therapy in Virologically Suppressed People Living With HIV and Factors Associated With Switching to Tritherapy : a Real-life Cohort","status":"COMPLETED","sponsor":"Tourcoing Hospital","startDate":"2011-01-01","conditions":"HIV Infections","enrollment":580},{"nctId":"NCT04066036","phase":"","title":"Population Effectiveness of Dolutegravir Implementation in Sub-Saharan Africa","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2019-05-14","conditions":"HIV-1-infection","enrollment":1000},{"nctId":"NCT00106171","phase":"PHASE4","title":"Anti-HIV Medications for People Recently Infected With HIV","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2005-05","conditions":"HIV Infections","enrollment":113},{"nctId":"NCT02707926","phase":"","title":"The Lymphoid Tissue Pharmacology of Antiretroviral Drugs","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2023-03-25","conditions":"HIV Infection","enrollment":""},{"nctId":"NCT04340388","phase":"PHASE4","title":"Contribution of Dolutegravir to Obesity and Cardiovascular Disease","status":"COMPLETED","sponsor":"Augusta University","startDate":"2020-09-17","conditions":"HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases","enrollment":10},{"nctId":"NCT05545319","phase":"PHASE2","title":"A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2022-12-13","conditions":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised","enrollment":""},{"nctId":"NCT02924389","phase":"PHASE4","title":"Dolutegravir in Reservoirs","status":"TERMINATED","sponsor":"Emory University","startDate":"2016-09","conditions":"HIV","enrollment":22},{"nctId":"NCT05525156","phase":"PHASE2","title":"The Effect of Aspirin on HIV Disease Progression Among HIV- Infected Individuals Initiating Anti- Retroviral Therapy","status":"SUSPENDED","sponsor":"Muhimbili University of Health and Allied Sciences","startDate":"2020-03-02","conditions":"Hiv, Cardiovascular Diseases","enrollment":454},{"nctId":"NCT01650558","phase":"NA","title":"Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-11","conditions":"HIV","enrollment":1499},{"nctId":"NCT00145795","phase":"PHASE4","title":"A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2004-04","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT04039217","phase":"PHASE4","title":"Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-09-30","conditions":"ART, HIV","enrollment":20},{"nctId":"NCT01559805","phase":"NA","title":"Intervention to Improve Engagement in Care Among Newly Diagnosed HIV-positive Men","status":"COMPLETED","sponsor":"Columbia University","startDate":"2012-11","conditions":"HIV, Patient Compliance","enrollment":202},{"nctId":"NCT01118767","phase":"NA","title":"Evaluation of a Computer-Based System Using Cell Phones for HIV People in Peru","status":"COMPLETED","sponsor":"Universidad Peruana Cayetano Heredia","startDate":"2010-05-01","conditions":"HIV, Adherence, Sexual Behavior","enrollment":210},{"nctId":"NCT00260078","phase":"PHASE1, PHASE2","title":"Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-02","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT00006604","phase":"PHASE1, PHASE2","title":"Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-11","conditions":"HIV Infections","enrollment":195},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT02028403","phase":"PHASE1","title":"Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-06","conditions":"HIV Infections","enrollment":8},{"nctId":"NCT00016718","phase":"PHASE1, PHASE2","title":"Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-08","conditions":"HIV Infections","enrollment":43},{"nctId":"NCT00000891","phase":"PHASE2","title":"Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT00001068","phase":"PHASE2","title":"A Study of Disease Progression and Anti-HIV Treatments","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":210},{"nctId":"NCT00000872","phase":"PHASE2","title":"Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT00001091","phase":"PHASE1","title":"Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT00001083","phase":"PHASE2","title":"Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":240},{"nctId":"NCT00099632","phase":"PHASE2","title":"Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-03","conditions":"HIV Infections","enrollment":484},{"nctId":"NCT00110812","phase":"PHASE2","title":"Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-09","conditions":"HIV Infections","enrollment":267},{"nctId":"NCT00000947","phase":"NA","title":"A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Mycobacterium Avium-intracellulare Infection, HIV Infections","enrollment":850},{"nctId":"NCT00102960","phase":"PHASE3","title":"Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-07","conditions":"HIV Infections","enrollment":377},{"nctId":"NCT00001024","phase":"NA","title":"The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT00051831","phase":"NA","title":"Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-10","conditions":"HIV Infections","enrollment":19},{"nctId":"NCT00012519","phase":"PHASE1, PHASE2","title":"Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":29},{"nctId":"NCT00007202","phase":"PHASE2","title":"Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT00099671","phase":"PHASE1","title":"Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-04","conditions":"HIV Infections","enrollment":25},{"nctId":"NCT00013871","phase":"NA","title":"Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis B, Measles","enrollment":300},{"nctId":"NCT00051090","phase":"NA","title":"Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis B","enrollment":""},{"nctId":"NCT00005758","phase":"PHASE3","title":"Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":472},{"nctId":"NCT00001108","phase":"PHASE1","title":"A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT00038259","phase":"NA","title":"Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":21},{"nctId":"NCT00257127","phase":"NA","title":"Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-02","conditions":"HIV Infections","enrollment":101},{"nctId":"NCT00006066","phase":"PHASE1","title":"Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":92},{"nctId":"NCT00001048","phase":"PHASE2","title":"Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Leukoencephalopathy, Progressive Multifocal","enrollment":90},{"nctId":"NCT00008866","phase":"PHASE2","title":"Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug Therapy","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00006291","phase":"PHASE2","title":"Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT00100581","phase":"NA","title":"Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis C","enrollment":2},{"nctId":"NCT00011011","phase":"PHASE1, PHASE2","title":"Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-02","conditions":"HIV Infections","enrollment":94},{"nctId":"NCT00021489","phase":"PHASE2","title":"Mycophenolate Mofetil and Abacavir Treatment in HIV Patients With Failed Anti-HIV Treatment","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00027339","phase":"PHASE2","title":"Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":53},{"nctId":"NCT00050921","phase":"NA","title":"Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT00036452","phase":"PHASE2","title":"A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":402},{"nctId":"NCT00015704","phase":"NA","title":"Effect of Interleukin-2 on HIV Treatment Interruption","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":80},{"nctId":"NCT00086359","phase":"PHASE3","title":"Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-07","conditions":"HIV Infections","enrollment":19},{"nctId":"NCT00102206","phase":"PHASE2","title":"A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT00006339","phase":"PHASE2","title":"Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00006495","phase":"PHASE1","title":"Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":80},{"nctId":"NCT00050063","phase":"","title":"Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":78},{"nctId":"NCT00000859","phase":"NA","title":"A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":1300},{"nctId":"NCT00000914","phase":"NA","title":"A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":800},{"nctId":"NCT00000943","phase":"NA","title":"A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT00000916","phase":"PHASE2","title":"A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":399},{"nctId":"NCT00000924","phase":"PHASE2","title":"A Study to Compare Two Different Anti-HIV Drug Regimens","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00000948","phase":"PHASE2","title":"Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1998-02","conditions":"HIV Infections","enrollment":72},{"nctId":"NCT00000902","phase":"PHASE1","title":"A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":217},{"nctId":"NCT00000896","phase":"NA","title":"A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT00000825","phase":"PHASE2","title":"The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1998-05","conditions":"HIV Infections","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6630,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Antiretroviral Combinations"],"phase":"marketed","status":"active","brandName":"Antiretroviral/Anti HIV","genericName":"Antiretroviral/Anti HIV","companyName":"MSD Pharmaceuticals LLC","companyId":"msd-pharmaceuticals-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antiretroviral drugs inhibit HIV replication by targeting viral enzymes or blocking viral entry into CD4+ T cells. Used for HIV-1 infection (treatment and prevention).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}